Issues in Pharmacological Treatment

  • George M. Simpson
  • Edmond H. Pi


The history of psychopharmacology is only three and a half decades old, dating back to the discovery of the first neuroleptic (chlorpromazine) in the early 1950s. This discovery may be considered one of the major advances in twentieth-century medicine. Like most advances, the introduction of chlorpromazine led to a period of rapidly expanding use, if not overuse, followed by a more gradual delineation of the specific areas of the drug’s usefulness.


Tardive Dyskinesia Neuroleptic Malignant Syndrome Antipsychotic Agent Lithium Treatment Lithium Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. American Psychiatric Association. (1980). Diagnostic and statistical manual of mental disorders ( 3rd ed. ). Washington, DC: Author.Google Scholar
  2. Axelrod, J. (1976). Neurotransmitters. In R. E. Thompson (Ed.), Progress in psychology. San Francisco: Freeman.Google Scholar
  3. Beck, A. T., Hollon, S. D., Young, J. E., Bedrosian, R. C., & Budenz, D. (1985). Treatment of depression with cognitive therapy and amitriptyline. Archives of General Psychiatry, 42, 142–148.PubMedCrossRefGoogle Scholar
  4. Beckman, H. (1981). Drug Therapy of depression. Nervenarzt, 52, 135–146.Google Scholar
  5. Burrows, G. D., Davies, J., & Scoggio, B. A. (1972). Plasma concentration of nortriptyline and clinical response in depressive illness. Lancet, 2, 619–623.PubMedCrossRefGoogle Scholar
  6. Cade, J. F. J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 36, 349–352.Google Scholar
  7. Caroff, S. N. (1980). The neuroleptic malignant syndrome. Journal of Clinical Psychiatry, 41, 79–83.PubMedGoogle Scholar
  8. Cooper, J. J., & Simpson, G. M. (1976). The 24-hour lithium level as a prognostic indicator of dosage requirements: A 2-year follow-up study. American Journal of Psychiatry, 133, 440–443.PubMedGoogle Scholar
  9. Cooper, J. J., Simpson, G. M., Haher, E. J., & Bergner, P. E. (1975). Butaperazine pharmakinetics: Effect of dosage regimen in steady state blood levels. Archives of General Psychiatry, 32, 903–905.PubMedCrossRefGoogle Scholar
  10. Cooper, J. J., Simpson, G. M., & Lee J. H. (1976). Thymoleptic and neuroleptic drug plasma levels in psychiatry: Current status. International Review of Neurobiology, 19, 297–298.CrossRefGoogle Scholar
  11. Donlon, P. T., Meadow, A., Tupin, J. P., & Wahba, M. (1978). High vs standard dosage fluphenazine HCI in acute schizophrenia. Journal of Clinical Psychology, 39, 800–804.Google Scholar
  12. Fabre, L. F., & Mclendon, D. M. (1980). A double-blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Current Therapeutic Research, 27, 474–482.Google Scholar
  13. Falloon, I. R. H., Boyd, J. L., Mcgill, C. W., Ranzani, J., Moss, H. J., & Gilderman, A. M. (1982). Family management in the prevention of exacerbations of schizophrenia. New England Journal of Medicine, 306, 1437–1444.PubMedCrossRefGoogle Scholar
  14. Glassman, A. H., Kantor, S. J., & Shostake, M. (1975). Depression, delusions and drug response. American Journal of Psychiatry, 132, 716–719.PubMedGoogle Scholar
  15. Goldstein, M. J., Rodnick, E. H., & Evans, J. R. (1978). Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry, 35, 1169–1177.PubMedCrossRefGoogle Scholar
  16. Goodnick, P. J., Fieve, R. R., Meltzer, H. L., & Dunner, D. L. (1981). Lithium elimination half-life and duration of therapy. Clinical Pharmacology and Therapeutics, 29, 47–50.PubMedCrossRefGoogle Scholar
  17. Hansen, J. E., Christiansen, T. R., Elley, J., Hansen, L. J., Kragh-Sorensen, P., Larsen, N. E., Nestoft, J., & Hvidbeg, E. F. (1976). Clinical pharmacokinetic studies of perphenazine. British Journal of Clinical Pharmacology, 3, 915–923.Google Scholar
  18. Hogarty, G. E., Goldberg, S. C., & Schooler, N. R. (1974). Drug and sociotherapy in the aftercare of schizophrenic patients: III. Adjustment of non-relapsed patients. Archives of General Psychiatry, 31, 609–618.CrossRefGoogle Scholar
  19. Hollister, L. E. (1983). Clinical pharmacology of psychotherapeutic drugs. New York: Churchill Livingstone.Google Scholar
  20. Hollister, L. E., Curry, S. H., Derr, J. E., & Kantor, S. L. (1970). Studies of delayed action medication vs. plasma levels and urinary excretion of four different dosage forms of chlorpromazine. Clinical Pharmacology and Therapeutics, 11, 49–59.PubMedGoogle Scholar
  21. Kielholz, P. ( 1981, June). Comparison of oral and intravenous treatment in therpay-refractory repression. Paper presented at Third World Congress of Biological Psychiatry, Stockholm.Google Scholar
  22. Kline, N. S. (1974). Antidepressant medications: A more effective use by general practitioners, family physicians, internists and others. Journal of American Medical Association, 227, 1158–1160.CrossRefGoogle Scholar
  23. Kotin, J., Post, R. M., & Goodwin, F. K. (1973). Drug treatment of depressed patients referred for hospitalization. American Journal of Psychiatry, 130, 1139–1141.PubMedGoogle Scholar
  24. Leff, J. P., Kuipers, L., & Berkowitz, R. (1983). In W. R. McFarlane (Ed.), Family therapy in schizophrenia. New York: Guilford Press.Google Scholar
  25. Levinson, D. F., & Simpson, G. M. (1986). Neuroleptic induced EPS with fever: Heterogeneity of the “neuroleptic malignant syndrome.” Archives of General Psychiatry, 43, 839–848.PubMedCrossRefGoogle Scholar
  26. Liberman, R. P., & Eckman, T. (1981). Behavior Therapy vs. insight-oriented therapy for repeated suicide at- temptors. Archives of General Psychiatry, 38, 1126–1130.PubMedCrossRefGoogle Scholar
  27. Loo, J. J. K., Midha, J. K., & McGilveray, I. J. (1980). Pharmacokinetics of chlorpromazine in normal volunteers. Community Psychopharmacology, 4, 121–129.Google Scholar
  28. Luborsky, L., Singer, J., & Luborsky, L. (1975). Comparative studies of psychotherapies. Archives of General Psychiatry, 32, 995–1008.PubMedCrossRefGoogle Scholar
  29. Magliozzi, J. R., Hollister, L. E., Arnold, J. V., & Earle, G. M. (1981). Relationship of serum haloperidol levels to clinical response in schizophrenic patients. American Journal of Psychiatry, 138, 365–367.PubMedGoogle Scholar
  30. Mason, A. S., & Granacher, R. P. (1976). Basic principles of rapid neuroleptization. Disease of the Nervous System, 37, 547–551.Google Scholar
  31. May, R. (1968). Treatment of schizophrenia: A comparative study of five treatment methods. New York: Science House.Google Scholar
  32. Mahler, H., & Okada, T. (1977). Benzodiazepine receptors: Demonstration in the central nervous system. Science, 198, 849–851.CrossRefGoogle Scholar
  33. Niemegeers, C. J. E., & Janssen, P. A. J. (1979). A systematic study of the pharmacological activities of dopamine antagonists. Life Science, 24, 2201–2216.CrossRefGoogle Scholar
  34. Pi, E. H., & Simpson, G. M. (1985). New antidepressants: A review. Hospital Formulary, 20, 580–588.Google Scholar
  35. Pi, E. H., & Simpson, G. M. (in press). Prevention of tardive dyskinesia. In N. S. Shah & A. G. Donald (Eds.), Neurobehavioral dysfunction induced by psychotherapeutic agents: Neurophysiological, neuropharmacological bases and clinical management, New York: Plenum Press.Google Scholar
  36. Reisberg, J., & Gershon, S. (1979). Side effects associated with lithium therapy. Archives of General Psychiatry, 36, 879–887.PubMedCrossRefGoogle Scholar
  37. Rickels, K. (1981). Are benzodiazepines overused and abused? Journal of Clinical Pharmacology, 11, 71–83.Google Scholar
  38. Rimon, R., & Rakkolainan, V. (1968). Lithium iodide in the treatment of confusional states. British Journal of Psychology, 114, 109–110.CrossRefGoogle Scholar
  39. Rivera-Calimlim, L., Castaneda, L., & Lasagna, L. (1973). Effects of mode of management on plasma chlor- promazine in psychiatric patients. Clinical Pharmacology Therapy, 14, 978–986.Google Scholar
  40. Robinson, D., Nies, A., Corcella, J., & Cooper. T. (1981). Phenelzine plasma levels, pharmacokinetics and clinical outcome. Psychopharmacology Bulletin, 17, 154–157.Google Scholar
  41. Schou, M. (1958). Lithium studies 3: Distribution between serum and tissues. Acta Pharmacologica et Toxicologica, 15, 115–124.CrossRefGoogle Scholar
  42. Schou, M., Juel-Nielsen, N., Stromgren, E., & Voldby, H. (1954). The treatment of manic psychoses by the administration of lithium salts. Acta Pharmacologica et Toxicologica, 17, 250–260.Google Scholar
  43. Sheenan, D. V. (1982). Current perspectives in the treatment of panic and phobic disorders. Drug Therapy, 12, 173–193.Google Scholar
  44. Simpson, G. M., & Pi, E. H. (1981). Pharmacokinetics of antipsychotic agents. In B. Angrist (Ed.), Recent advances in neuroPsychopharmacology. New York: Oxford.Google Scholar
  45. Simpson, G. M., & Yadalam K. (1977). Blood levels of neuroleptics: State of the art. Journal of Clinical Psychiatry, 46, 22–28.Google Scholar
  46. Simpson, G. M., Pi., E. H., & Sramek, J. J. (1981). Adverse effects of antipsychotic agents. Drugs, 21, 138–151.Google Scholar
  47. Simpson, G. M., Pi, E. H., & Sramek, J. J. (1982). Management of tardive dyskinesia: Current update. Drugs, 23, 381–383.PubMedCrossRefGoogle Scholar
  48. Simpson, G. M., Pi, E. H., & White, K. L. (1983). Plasma drug levels and clinical response to antidepressants. Journal of Clinical Psychiatry, 44, 27–34.PubMedGoogle Scholar
  49. Simpson, G. M., Pi, E. H., & Sramek, J. J. (1984). Neuroleptics and antipsychotics. In M. N. G. Dukes (Ed.), Meyler’s side effects of drugs (10th ed.). Amsterdam: Elsevier Science Publishing.Google Scholar
  50. Squires, R. F., & Braestrup, C. (1977). Benzodiazepine receptors in rat brain. Nature, 266, 732–734.PubMedCrossRefGoogle Scholar
  51. Stone, A. (1983). The new paradox of psychiatric malpractice. New England Journal of Medicine, 311, 1384–1387.CrossRefGoogle Scholar
  52. Sulser, F. (1983). Mode of action of antidepressant drugs. Journal of Clinical Psychiatry, 44, 14–20.PubMedGoogle Scholar
  53. Tallman, J. F., Paul, S. M., Skolnick, P., & Gallagher, D. W. (1980). Receptors for the age of anxiety: Pharmacology of the benzodiazepines. Science, 207, 274–281.PubMedCrossRefGoogle Scholar
  54. Taylor, M. A., & Abrams, R. (1981). Prediction of treatment response in mania. Archives of General Psychiatry, 38, 800–803.PubMedCrossRefGoogle Scholar
  55. Tyrer, P. (1978). Drug treatment of psychiatric patients in general practice. British Medical Journal, 2, 1008–1010.PubMedCrossRefGoogle Scholar
  56. Wegner, J. T., & Kane, J. M. (1982). Follow-up study on the reversibility of tardive dyskinesia. American Journal of Psychiatry, 139, 308–372.Google Scholar
  57. Weissman, M. M. (1978). Psychotherapy and its relevance to the pharmacotherapy of affective disorders: From ideology to evidence. In M. A. Lipton, A. Dimascio, & K. F. Killom (Eds.), Psychopharmacology: A generation of progress. New York: Raven Press.Google Scholar
  58. Wode-Helgodt, J., Borg, S. Fyro, J., & Sedvall, G. (1978). Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with doses of chlorpromazine. Acta Psychiatrica Scandinavica, 58, 149–173.Google Scholar
  59. Yosselson-Superstein, S., Sternik, D., & Liebanzon, D. (1979). Prescribing patterns in psychiatric hospitals in Israel. Acta Psychiatrica Scandinavica 60, 477–482.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • George M. Simpson
    • 1
  • Edmond H. Pi
    • 2
  1. 1.Department of PsychiatryThe Medical College of Pennsylvania at EPPIPhiladelphiaUSA
  2. 2.Department of PsychiatryUniversity of Southern California, School of MedicineLos AngelesUSA

Personalised recommendations